Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses

Molecular Genetics and Metabolism

Volumn 111, Issue 4, 2014, Pages 533-538

  Lin, Hsiang Yu ^a,b,c,d   Shih, Shou Chuan ^a,b   Chuang, Chih Kuang ^b,e,f   Lee, Kuo Sheng ^a,b,c   Chen, Ming Ren ^a,b,c   Lin, Hung Ching ^a,b   Chiu, Pao Chin ^g   Niu, Dau Ming ^d,h   Lin, Shuan Pei ^a,b,c,i  

^a MACKAY MEDICAL COLLEGE   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^g KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

Enzyme replacement therapy; Hearing loss; Mucopolysaccharidoses; Pure tone audiometry

Indexed keywords

ADULT; AIR CONDUCTION; ARTICLE; AUDITORY THRESHOLD; BONE CONDUCTION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE SEVERITY; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GROUPS BY AGE; HEARING IMPAIRMENT; HUMAN; MALE; MUCOPOLYSACCHARIDOSIS; PREVALENCE; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; TYMPANOMETRY; ADOLESCENT; AGE DISTRIBUTION; COMPLICATION; HEARING LOSS; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; MALE; MUCOPOLYSACCHARIDOSES; PREVALENCE; YOUNG ADULT;

EID: 84897573493     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.02.003     Document Type: Article

References (20)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, B. Vogelstein (Eds.).
2. Chuang C.K., Lin S.P. Neurochemical changes and therapeutical approaches in mucopolysaccharidoses. Neurochemistry of Metabolic Diseases-Lysosomal Storage Diseases, Phenylketonuria and Canavan Disease 2007, 1-20. Transworld Research Network, Trivandrum, India. S. Surendran, M. Aschner, M. Bhatnagar (Eds.).
3. Lin H.Y., Lin S.P., Chuang C.K., Niu D.M., Chen M.R., Tsai F.J., Chao M.C., Chiu P.C., Lin S.J., Tsai L.P., Hwu W.L., Lin J.L. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am. J. Med. Genet. A. 2009, 149A:960-964.
4. Schleier E., Streubel H.G. Phoniatric aspects of children with mucopolysaccharidosis. Folia. Phoniatr. (Basel). 1976, 28:65-72.
5. Peck J.E. Hearing loss in Hunter's syndrome-mucopolysaccharidosis II. Ear. Hear. 1984, 5:243-246.
6. Wold S.M., Derkay C.S., Darrow D.H., Proud V. Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol. 2010, 74:27-31.
7. Hendriksz C.J., Al-Jawad M., Berger K.I., Hawley S.M., Lawrence R., Mc Ardle C., Summers C.G., Wright E., Braunlin E. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J. Inherit. Metab. Dis. 2013, 36:309-322.
8. World Health Organization WHO ear and hearing disorders survey protocol for a population-based survey of prevalence and causes of deafness and hearing impairment and other ear disorders Retrieved from, (on 05-11-13). http://whqlibdoc.who.int/hq/1999/WHO_PBD_PDH_99.8(1).pdf.
9. Steele D.J., Susman J., McCurdy F.A. Student guide to primary care: making the most of your early clinical experience. Elsevier Health Sciences 2003, 370-392. (ISBN 978-1-56053-545-4).
10. Napiontek U., Keilmann A. Hearing impairment in patients with mucopolysaccharidoses. Acta. Paediatrica. Suppl. 2006, 451:114.
11. Keilmann A., Nakarat T., Bruce I.A., Molter D., Malm G., HOS Investigators Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey. J. Inherit. Metab. Dis. 2012, 35:343-353.
12. Chuang C.K., Lin S.P., Chung S.F. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua. Yi. Xue. Za. Zhi. (Taipei). 2001, 64:15-22.
13. Mazzoli M., Camp G.V., Newton V., Girbini N., Declau F., Parving A. Recommendation for the description of genetic and audiological data for families with nonsyndromic heredity hearing impairment. Audiolog. Med. 2003, 1:148-150.
14. Pascolini D., Smith A. Hearing impairment in 2008: a compilation of available epidemiological studies. Int. J. Audiol. 2009, 48:473-485.
15. Hajioff D., Hegemann S., Conti G., Beck M., Sunder-Plassmann G., Widmer U., Mehta A., Keilmann A. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur. J. Clin. Invest. 2006, 36:663-667.
16. Komori M., Sakurai Y., Kojima H., Ohashi T., Moriyama H. Long-term effect of enzyme replacement therapy with Fabry disease. Int. J. Otolaryngol. 2013, 2013:282487.
17. Brands M.M., Oussoren E., Ruijter G.J., Vollebregt A.A., van den Hout H.M., Joosten K.F., Hop W.C., Plug I., van der Ploeg A.T. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol. Genet. Metab. 2013, 109:70-76.
18. Hong S.H., Chu H., Kim K.R., Ko M.H., Kwon S.Y., Moon I.J., Chung W.H., Cho Y.S., Kim C.H., Suh M.W., Choi E.W., Sohn Y.B., Park S.W., Kim S.H., Cho S.Y., Ko A.R., Jin D.K. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II. Am. J. Med. Genet. A. 2012, 158A:2131-2138.
19. O'Connor L.H., Erway L.C., Vogler C.A., Sly W.S., Nicholes A., Grubb J., Holmberg S.W., Levy B., Sands M.S. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J. Clin. Invest. 1998, 101:1394-1400.
20. Simmons M.A., Bruce I.A., Penney S., Wraith E., Rothera M.P. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol. 2005, 69:589-595.